Jun 2026 (Q2 FY26) — Aug 12, 2026
PolyPid Q2 FY26 — FDA Priority Review and Azurity Partnership Reshape Company Profile
Read the full callPolyPid (PYPD) earnings
- Jun 2025
- Jun 2026 (Q2 FY26)
- Dec 2025
PolyPid earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2025 | Not in the filed figures for the quarter to jun 2025. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2025 | Not in the filed figures for the quarter to jun 2025. No older figure is substituted. | ||
| Net profit | -10.0 | Quarterly, as filed | Quarter to Jun 2025 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$4.72 −3.67% · −$0.18
Performance +40.9% 1Y
1Y: $3.35 on 15 Oct 2025 → $4.72. High $5.58 (6 Jul 2026), low $3.18 (22 Oct 2025).
- Previous close
- $4.9
- 52-week range
- $3.18 – $5.58
- One year
- +40.90%
Overview
- Symbol
- PYPD
- Sector
- Health Care
- Industry
- Surgical & Medical Instruments & Apparatus
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
PolyPid earnings calls (PYPD)
Financials
What the filings say
Net profit, year on year: −59% (quarter to jun 2025 against jun 2024).
| Line item | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|
| Operating profit | -11 | -12 | -6 | -6 | -9 |
| Other income | 0 | -0 | -0 | -0 | -1 |
| Profit before tax | — | — | -6 | -6 | -10 |
| Tax rate | — | — | −0.2% | −0.0% | −0.5% |
| Net profit | -10 | -12 | -6 | -6 | -10 |
| EPS ($ per share) | -0.56 | -0.61 | -3.95 | -1.25 | -0.78 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Reserves | — | -93 | -132 | -175 | -214 | -238 | -267 | -301 |
| Total liabilities | — | 121 | 3 | 8 | 20 | 17 | 18 | 11 |
| Fixed assets | — | 6 | 6 | 9 | 9 | 8 | 6 | 5 |
| Total assets | — | 34 | 76 | 44 | 26 | 15 | 25 | 22 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -17 | -17 | -22 | -32 | -34 | -17 | -22 | -28 |
| Cash from investing | 11 | -24 | -41 | 37 | 17 | 4 | -0 | -7 |
| Cash from financing | 9 | 38 | 63 | 1 | 16 | 10 | 32 | 25 |
| Net cash flow | — | — | — | — | — | -3 | 10 | -9 |
| Capital expenditure | -3 | -1 | -1 | -3 | -2 | -0 | -0 | -0 |
| Free cash flow | -20 | -18 | -22 | -35 | -36 | -17 | -22 | -28 |
Insider filings
No filings in the last 12 months.
No officer, director or 10% owner of PYPD filed a Form 4 in this window. That is a statement about filings, not about ownership — see the note below.
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for PolyPid Ltd.
Free account. Everything above stays public.
Write why you follow PolyPid Ltd. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading